Comparison · NCT01654536-b89274fa
Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: Number of Subjects With Development of or Worsening in Lens Opacities.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ciclesonide Nasal Aerosol vs Ciclesonide Nasal Spray: Number of Subjects With Development of or Worsening in Lens Opacities. Trial comparisons, record NCT01654536-b89274fa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01654536-b89274fa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.139 | 0.107 | 0.178 | wilson | |
| Risk in group 2 | 0.143 | 0.111 | 0.183 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00428 | -0.0548 | 0.0463 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.97 | 0.679 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 0.965 | 0.638 | 1.46 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ciclesonide Nasal Aerosol than on Ciclesonide Nasal Spray | 234 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ciclesonide Nasal Aerosol | Zetonna (ciclesonide) nasal aerosol 74 mcg~ciclesonide nasal aerosol: ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol) | 51 | 367 | OG000 |
| Group 2 | Ciclesonide Nasal Spray | Omnaris (ciclesonide) nasal spray 200 mcg~ciclesonide nasal spray: ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray) | 53 | 370 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects With Development of or Worsening in Lens Opacities.
- Description
- Time frame
- 0-6 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
- NCT number
- NCT01654536
- Phases
- PHASE4
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- ciclesonide nasal aerosol, ciclesonide nasal spray
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Results first posted
- 2014-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01654536?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01654536-b89274fa